These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 23403818)
1. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Fujiwara S; Wada H; Kawada J; Kawabata R; Takahashi T; Fujita J; Hirao T; Shibata K; Makari Y; Iijima S; Nishikawa H; Jungbluth AA; Nakamura Y; Kurokawa Y; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Nakayama E; Mori M; Doki Y Br J Cancer; 2013 Mar; 108(5):1119-25. PubMed ID: 23403818 [TBL] [Abstract][Full Text] [Related]
2. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers. Oshima Y; Shimada H; Yajima S; Nanami T; Matsushita K; Nomura F; Kainuma O; Takiguchi N; Soda H; Ueda T; Iizasa T; Yamamoto N; Yamamoto H; Nagata M; Yokoi S; Tagawa M; Ohtsuka S; Kuwajima A; Murakami A; Kaneko H J Gastroenterol; 2016 Jan; 51(1):30-4. PubMed ID: 25906289 [TBL] [Abstract][Full Text] [Related]
3. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. Stockert E; Jäger E; Chen YT; Scanlan MJ; Gout I; Karbach J; Arand M; Knuth A; Old LJ J Exp Med; 1998 Apr; 187(8):1349-54. PubMed ID: 9547346 [TBL] [Abstract][Full Text] [Related]
4. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Wang Y; Wu XJ; Zhao AL; Yuan YH; Chen YT; Jungbluth AA; Gnjatic S; Santiago D; Ritter G; Chen WF; Old LJ; Ji JF Cancer Immun; 2004 Nov; 4():11. PubMed ID: 15516106 [TBL] [Abstract][Full Text] [Related]
5. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. Maio M; Coral S; Sigalotti L; Elisei R; Romei C; Rossi G; Cortini E; Colizzi F; Fenzi G; Altomonte M; Pinchera A; Vitale M J Clin Endocrinol Metab; 2003 Feb; 88(2):748-54. PubMed ID: 12574209 [TBL] [Abstract][Full Text] [Related]
6. Urine antibody against human cancer antigen NY-ESO-1. Jäger D; Stockert E; Karbach J; Herrlinger K; Atmaca A; Arand M; Chen YT; Gnjatic S; Old LJ; Knuth A; Jäger E Cancer Immun; 2002 Aug; 2():10. PubMed ID: 12747755 [TBL] [Abstract][Full Text] [Related]
7. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. Kageyama S; Wada H; Muro K; Niwa Y; Ueda S; Miyata H; Takiguchi S; Sugino SH; Miyahara Y; Ikeda H; Imai N; Sato E; Yamada T; Osako M; Ohnishi M; Harada N; Hishida T; Doki Y; Shiku H J Transl Med; 2013 Oct; 11():246. PubMed ID: 24093426 [TBL] [Abstract][Full Text] [Related]
8. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. Ademuyiwa FO; Bshara W; Attwood K; Morrison C; Edge SB; Karpf AR; James SA; Ambrosone CB; O'Connor TL; Levine EG; Miliotto A; Ritter E; Ritter G; Gnjatic S; Odunsi K PLoS One; 2012; 7(6):e38783. PubMed ID: 22761704 [TBL] [Abstract][Full Text] [Related]
9. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. Kawada J; Wada H; Isobe M; Gnjatic S; Nishikawa H; Jungbluth AA; Okazaki N; Uenaka A; Nakamura Y; Fujiwara S; Mizuno N; Saika T; Ritter E; Yamasaki M; Miyata H; Ritter G; Murphy R; Venhaus R; Pan L; Old LJ; Doki Y; Nakayama E Int J Cancer; 2012 Feb; 130(3):584-92. PubMed ID: 21413013 [TBL] [Abstract][Full Text] [Related]
10. [Analysis of CT antigen expression and humoral immunogenicity of NY-ESO-1 protein in gastric carcinoma]. Wu XJ; Wang Y; Ji JF Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):252-6. PubMed ID: 15968313 [TBL] [Abstract][Full Text] [Related]
11. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Jäger E; Stockert E; Zidianakis Z; Chen YT; Karbach J; Jäger D; Arand M; Ritter G; Old LJ; Knuth A Int J Cancer; 1999 Oct; 84(5):506-10. PubMed ID: 10502728 [TBL] [Abstract][Full Text] [Related]
12. Serum NY-ESO-1 and p53 antibodies as useful tumor markers in gastric cancer. Kawada J; Saito T; Kurokawa Y; Kawabata R; Takeno A; Takeoka T; Nose Y; Wada H; Eguchi H; Doki Y; Ann Gastroenterol Surg; 2024 Mar; 8(2):243-250. PubMed ID: 38455491 [TBL] [Abstract][Full Text] [Related]
13. Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein. Komatsu N; Jackson HM; Chan KF; Oveissi S; Cebon J; Itoh K; Chen W Mol Immunol; 2013 Jul; 54(3-4):465-71. PubMed ID: 23454162 [TBL] [Abstract][Full Text] [Related]
14. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Sugita Y; Wada H; Fujita S; Nakata T; Sato S; Noguchi Y; Jungbluth AA; Yamaguchi M; Chen YT; Stockert E; Gnjatic S; Williamson B; Scanlan MJ; Ono T; Sakita I; Yasui M; Miyoshi Y; Tamaki Y; Matsuura N; Noguchi S; Old LJ; Nakayama E; Monden M Cancer Res; 2004 Mar; 64(6):2199-204. PubMed ID: 15026363 [TBL] [Abstract][Full Text] [Related]
15. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Türeci O; Mack U; Luxemburger U; Heinen H; Krummenauer F; Sester M; Sester U; Sybrecht GW; Sahin U Cancer Lett; 2006 May; 236(1):64-71. PubMed ID: 15992994 [TBL] [Abstract][Full Text] [Related]
16. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Kawabata R; Wada H; Isobe M; Saika T; Sato S; Uenaka A; Miyata H; Yasuda T; Doki Y; Noguchi Y; Kumon H; Tsuji K; Iwatsuki K; Shiku H; Ritter G; Murphy R; Hoffman E; Old LJ; Monden M; Nakayama E Int J Cancer; 2007 May; 120(10):2178-84. PubMed ID: 17278093 [TBL] [Abstract][Full Text] [Related]
17. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. Qian F; Gnjatic S; Jäger E; Santiago D; Jungbluth A; Grande C; Schneider S; Keitz B; Driscoll D; Ritter G; Lele S; Sood A; Old LJ; Odunsi K Cancer Immun; 2004 Nov; 4():12. PubMed ID: 15521719 [TBL] [Abstract][Full Text] [Related]
18. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. Ishihara M; Tono Y; Miyahara Y; Muraoka D; Harada N; Kageyama S; Sasaki T; Hori Y; Soga N; Uchida K; Shiraishi T; Sato E; Kanda H; Mizuno T; Webster GA; Ikeda H; Katayama N; Sugimura Y; Shiku H Cancer Immunol Immunother; 2020 Apr; 69(4):663-675. PubMed ID: 31980914 [TBL] [Abstract][Full Text] [Related]
19. Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group. Myšíková D; Adkins I; Hradilová N; Palata O; Šimonek J; Pozniak J; Kolařík J; Skallová-Fialová A; Špíšek R; Lischke R J Thorac Oncol; 2017 Feb; 12(2):249-257. PubMed ID: 27793776 [TBL] [Abstract][Full Text] [Related]
20. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Yuan J; Adamow M; Ginsberg BA; Rasalan TS; Ritter E; Gallardo HF; Xu Y; Pogoriler E; Terzulli SL; Kuk D; Panageas KS; Ritter G; Sznol M; Halaban R; Jungbluth AA; Allison JP; Old LJ; Wolchok JD; Gnjatic S Proc Natl Acad Sci U S A; 2011 Oct; 108(40):16723-8. PubMed ID: 21933959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]